GLP-1受体激动剂与系统性红斑狼疮及狼疮肾炎患者心脏和肾脏不良结局风险
该研究采用目标试验模拟方法,利用美国多中心电子健康记录数据库,比较GLP-1受体激动剂与DPP4抑制剂在系统性红斑狼疮合并2型糖尿病患者中的心血管和肾脏结局。结果显示,GLP-1受体激动剂组的主要不良心血管事件、静脉血栓栓塞、肾脏疾病进展和全因死亡风险均低于DPP4抑制剂组,在狼疮肾炎患者中MACE和肾脏疾病进展风险也较低。
要点
- 在SLE合并T2D患者中,GLP-1RA较DPP4i与更低的主要不良心血管事件风险相关(HR 0.66,95%CI 0.48-0.91)。
- GLP-1RA较DPP4i与更低的静脉血栓栓塞风险(HR 0.49,95%CI 0.24-0.97)和全因死亡风险(HR 0.26,95%CI 0.10-0.68)相关。
- 在狼疮肾炎患者中,GLP-1RA与较低的MACE和肾脏疾病进展风险 similarly 相关。
核心结论
- 在狼疮合并2型糖尿病患者中,与DPP4抑制剂相比,GLP-1受体激动剂使用与更低的心血管和肾脏不良结局及死亡风险相关。
研究设计与样本
- 采用目标试验模拟方法,利用美国多中心电子健康记录数据库,比较GLP-1RA与DPP4i在SLE合并T2D患者中的心血管和肾脏结局。
- 使用倾向评分重叠权重模拟治疗组间的随机化,采用Cox回归比较加权人群的风险比。
- 共纳入910例GLP-1RA起始者和1004例DPP4i起始者,其中分别有267例和324例狼疮肾炎患者。
主要发现
- GLP-1RA组较DPP4i组主要不良心血管事件风险更低(HR 0.66,95%CI 0.48-0.91)。
- GLP-1RA组较DPP4i组静脉血栓栓塞风险更低(HR 0.49,95%CI 0.24-0.97)。
- GLP-1RA组较DPP4i组肾脏疾病进展风险更低(HR 0.77,95%CI 0.60-0.98)。
- GLP-1RA组较DPP4i组全因死亡风险更低(HR 0.26,95%CI 0.10-0.68)。
- 在狼疮肾炎患者中,GLP-1RA使用与较低的MACE和肾脏疾病进展风险 similarly 相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have cardioprotective and kidney-protective benefits among patients with type 2 diabetes (T2D). We sought to determine whether GLP-1RA use improves cardiovascular (CV) and kidney outcomes among patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN). METHODS: We emulated a pragmatic target trial to evaluate the impact of GLP-1RA versus comparator hypoglycemic agents, dipeptidyl peptidase 4 inhibitors (DPP4i), on CV and kidney outcomes among patients with SLE and T2D using a large, US multicenter electronic health record database. We used propensity score overlap weighting to emulate randomization among treatment groups. Outcomes included major adverse CV events, venous thromboembolism (VTE), kidney disease progression (estimated glomerular filtration rate decline ≥ 30% or new onset end-stage kidney disease), and all-cause mortality. We used Cox regression to compare hazard ratios (HR) based on the weighted populations. In a secondary analysis, we only included patients with LN. RESULTS: There were 910 and 1,004 initiators of GLP-1RA and DPP4i, respectively, including 267 and 324 patients with LN, respectively. Baseline covariates were balanced after propensity score overlap weighting. The risks of major adverse cardiac events (MACEs; hazard ratio [HR] 0.66, 95% confidence interval [CI] 0.48-0.91), VTE (HR 0.49, 95% CI 0.24-0.97), kidney disease progression (HR 0.77, 95% CI 0.60-0.98), and all-cause mortality (HR 0.26, 95% CI 0.10-0.68) were lower with GLP-1RA versus DPP4i use. GLP-1RA use was similarly associated with lower risks of MACE and kidney disease progression among patients with LN. CONCLUSION: We found lower risks of adverse CV and kidney outcomes and mortality with GLP-1RA use compared with DPP4i use among patients with lupus and T2D.
引用
- Jorge A, Patel AV, Zhou B, et al. Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients With Systemic Lupus Erythematosus and Lupus Nephritis. Arthritis Rheumatol. 2025. PMID: 40994310. doi:10.1002/art.43403
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。